Logo

commercialization agreement

Mainz Biomed, Fugene Genetics Partner on Colorectal Cancer Test Launch in Israel

The deal is one of several struck this year by Mainz Biomed for the marketing of its stool sample-based ColoAlert molecular test for colorectal cancer.

Mainz Biomed Inks Commercialization Deals for Colorectal Cancer Test in UK, Spain

The test combines analysis of DNA, mRNA, and fecal immunohistochemistry to identify cancer in asymptomatic individuals from a stool sample.

Unilabs, Ambry Genetics Partner to Market Research-Use Genomic Testing Services Internationally

The companies aim to offer genetic testing for biopharma and government-sponsored research in Europe, Latin America, and the Middle East.

Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment

Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.

Prostatype Genomics, Life Genomics Ink Commercialization Deal for Prostate Cancer Test

Prostatype's test is designed to use gene expression and certain clinical measures to determine a prostate tumor's aggressiveness and guide treatment.

Aug 3, 2022

Codexis, Molecular Assemblies Ink Commercial License and Enzyme Supply Agreement

Feb 14, 2022

Mainz Biomed Partners with German Regional Lab on Colorectal Cancer Test Commercialization

Oct 12, 2021

Partnership Aims to Sequence African Genomes in Fight for Health Equity
Premium

Aug 10, 2021

Prenetics Gets CE-IVD Mark for Handheld, Reusable SARS-CoV-2 Test System

Jul 1, 2021

Bio-Rad Laboratories, Seegene Partner for Infectious Disease MDx Development

Jun 14, 2021

GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana

Apr 6, 2021

MyHealthChecked to Offer At-Home Coronavirus Test Kit Through UK Pharmacy Chain Boots

Mar 4, 2021

Genetic Technologies Inks US Commercialization Deal for COVID-19 Risk Test With Infinity Biologix

Feb 22, 2021

Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test

Jan 11, 2021

Seer Inks Commercial Agreements with Bruker, Thermo Fisher Scientific

Jan 7, 2021

CareDx, IDbyDNA Partner to Develop Infectious Disease Dx for Transplant Patients

Dec 1, 2020

Stilla Technologies Partners With ID-Solutions for Oncology MDx

Oct 29, 2020

Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company

Oct 14, 2020

ERS Genomics, FASMAC Sign Deal to Commercialize CRISPR-Cas9 Research Reagents in Japan

Sep 29, 2020

Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

Sep 15, 2020

ERS Genomics, Applied StemCell Ink Commercialization Agreement for CRISPR Services, Reagents

Aug 10, 2020

HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

Jul 13, 2020

OpGen to Distribute Menarini Silicon Cellsearch Platform in North America for COVID-19 Applications

Jul 7, 2020

Cancer Research UK, Abcam Partner to Develop Custom Antibodies for Cancer Research

Jul 1, 2020

Sherlock Biosciences, Binx Health Partner to Develop CRISPR-Based POC COVID-19 Test
Premium

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.